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Translational control of messenger RNAs (mRNAs) is a key aspect of neurobiology, defects
of which can lead to neurological diseases. In response to stimuli, local translation of
mRNAs is activated at synapses to facilitate long-lasting forms of synaptic plasticity, the
cellular basis for learning, and memory formation.Translation, as well as all other aspects of
RNA metabolism, is controlled in part by RNA binding proteins (RBPs) that directly interact
with mRNAs to form mRNA-protein complexes. Disruption of RBP function is becoming
widely recognized as a major cause of neurological diseases.Thus understanding the mech-
anisms that govern the interplay between translation control and RBP regulation in both
normal and diseased neurons will provide new opportunities for novel diagnostics and ther-
apeutic intervention. As a means of studying translational control, genome-wide methods
are emerging as powerful tools that have already begun to unveil mechanisms that are
missed by single-gene studies. Here, we describe the roles of RBPs in translational con-
trol, review genome-wide approaches to examine translational control, and discuss how
the application of these approaches may provide mechanistic insight into the pathogenic
underpinnings of RBPs in neurological diseases.
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INTRODUCTION
Analogous to DNA, which is organized and packed via strong
associations with histones in the nucleus, precursor, and mature
messenger RNAs (mRNAs) never exist as “naked” ribonucleic
acid sequences. After transcription in the nucleus, RNA bind-
ing proteins (RBPs) recognize cis-regulatory RNA elements within
precursor mRNA sequence to form messenger ribonucleoprotein
(mRNP) complexes. Again, analogous to DNA-binding proteins
such as transcription factors that regulate gene expression by bind-
ing to DNA elements in the promoters of genes, RBPs regulate
the fate of target RNAs by interacting with specific sequences or
RNA secondary structural features within the transcribed RNA
molecule. These cis-regulatory RNA elements can be found in
the 5′ and 3′ untranslated regions (UTRs), introns, and exons of
all protein-coding genes. RNA elements in 5′ and 3′ UTRs are
frequently involved in targeting RNA to specific cellular compart-
ments, affecting 3′ end formation, controlling RNA stability, and
regulating mRNA translation. RNA elements in introns and exons
are known to function as splicing enhancers or silencers to control
the process of precursor mRNA splicing (Jensen et al., 2009).
A genome-wide survey of 323 mouse RBPs by in situ hybridiza-
tion in the developing brain yielded the surprising result that
two-thirds of those RBPs are expressed in a cell type specific man-
ner (McKee et al., 2005). Compared to other cells in the body,
the complex structure and specialization of neurons explains the
need for having many RBPs to maintain proper neural function.
Consistent with the crucial roles of RBPs in regulating RNA home-
ostasis in the nervous system, mutations that impair RBP function
have been linked to severe neurological diseases such as Fragile
X syndrome (FXS), Fragile X-associated tremor/ataxia syndrome
(FXTAS), Amyotrophic lateral sclerosis (ALS), Frontotemporal
lobar dementia (FTLD), Spinal muscular atrophy (SMA), and
Myotonic dystrophy (Lukong et al., 2008). To understand the
impact of mutations within RBPs in neurodegeneration, we need
to elucidate the normal activities of RBPs in neurons. It is well-
known that RBPs are intimately involved with the regulation of
alternative splicing, a process by which numerous isoforms are
generated from a single genetic loci, and is in fact, more preva-
lent in the nervous system than in any other cell types (Yeo et al.,
2004; Wang et al., 2008a). RBPs are required to protect mRNAs
during their transport from the soma to distal axonal and den-
dritic locations, and once at these locations, RBPs mediate local
de novo synthesis of proteins (translation). Local translation at
or near axonal and dendritic synapses is the underlying mecha-
nism of synaptic plasticity (Sutton and Schuman, 2006), which
refers to the ability of synapses to undergo long-lasting biochemi-
cal and morphological changes in response to stimuli (Richter and
Klann, 2009). As a result, local translation is critical for cognition
and memory. Local synaptic translation is also critical for axon
guidance and nerve regeneration (Willis et al., 2005). Accordingly,
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pharmacological inhibition of protein synthesis prevents some
forms of synaptic plasticity in cultured neurons and attenuates
long-term memory in mice (Scharf et al., 2002; Kelleher et al.,
2004; Banko et al., 2005; Sutton and Schuman, 2006).
Given the significance of RBP biology and mRNA translation in
controlling neuron structure and function, advances in sequenc-
ing and microarray technology have sparked the development of
genome-wide methods that enable the neuroscience community to
dissect the roles that RBPs play in controlling mRNA translation in
the brain. Here we review how RBPs associate with different mRNP
complexes to regulate translation, summarize emerging genome-
wide methods that enable an unbiased examination of translation
on a global scale, and discuss how genome-wide studies using
these methods have and will continue to aid our understanding of
translational control in normal and pathological neurobiology.
MESSENGER RNP COMPLEXES AND TRANSLATIONAL
CONTROL
From synthesis to destruction, mRNAs are coated with RBPs that
sequester mRNA into mRNP complexes and ultimately influ-
ence their cellular fate. These mRNP complexes, as depicted in
Figure 1, are polysomes, RNA granules, RNA particles, stress gran-
ules (SGs), processing bodies (P-bodies), and RNA-induced silenc-
ing complexes (RISCs). This section provides a brief description
of these complexes and introduces RBPs with roles in translation
that associate with these complexes (for more details, see Kiebler
and Bassell, 2006; Sossin and DesGroseillers, 2006; Erickson and
Lykke-Andersen, 2011).
Polysome complexes are the centers of protein production and
are present in the cell body, axon, and dendrites of a neuron (Stew-
ard and Levy, 1982; Giuditta et al., 2002). RBPs such as Lin28
have been shown to decorate polysomes and promote translation
(Balzer and Moss, 2007). It is important to note, however, that
polysome-associated mRNAs can be translationally repressed. Sev-
eral groups have reported instances where translational inhibition
of certain proteins did not correspond to a decrease in ribosome
number on the encoding mRNAs (Olsen and Ambros, 1999; Braat
et al., 2004; Nottrott et al., 2006; Petersen et al., 2006). Such obser-
vations likely captured an event called ribosomal stalling, where
ribosomes temporarily or permanently stop elongating along tran-
scripts. The RBPs FMRP and Staufen have been shown to induce
ribosomal stalling (Thomas et al., 2009; Darnell et al., 2011).
MicroRNA-loaded RISCs (miRISCs), which also associate with
polysomes, can repress translation by promoting ribosomal paus-
ing (Maroney et al.,2006; Nottrott et al.,2006; Petersen et al.,2006).
For local translation to occur at synapses, mRNAs must be
transported from the soma to synapses. RNA particles and RNA
granules function to traffic mRNAs to designated subcellular com-
partments. These structures are complexes of mRNAs and inter-
acting RBPs, motor proteins, and adaptor proteins that tether the
RBPs to motor complexes. While in transit, transcripts are both
protected from degradation and are translationally repressed until
the appropriate signals are received. The RBP Zip-code binding
protein 1 (ZBP1) is a well-known regulator of mRNA transport
and translational repression (Huttelmaier et al., 2005). Other RBPs
such as Staufen, FMRP, and Pumilio also suppress translation of
FIGURE 1 | Messenger RNAs associate with several RNP structures
that influence their translational state. (A) Polysomes, sites of
translation, contain RBPs that activate (green spheres) or repress (red
spheres) translation. Following synthesis and processing, mRNA is
exported from the nucleus and transported throughout the cell along
microtubules via (B) RNA granules and (C) RNA particles. Repressor RBPs
(red spheres) are present within RNA particles to ensure that mRNAs are
not translated during transit. Messenger RNAs within RNA granules are
associated with translation initiation machinery (light blue spheres)
including ribosomes, suggesting that translation has commenced but is
halted during transit. The translational fate of mRNA is dictated in part by
the RBPs bound to them. If targeted by repressor RBPs or miRISCs (blue
squares), mRNAs will associate with (D) stress granules, (E) processing
bodies, or (F) miRISC structures resulting in either degradation or
translational repression. Some RBPs present in neuronal RNP complexes
are listed.
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transcripts in RNA particles and RNA granules (Kiebler and Des-
Groseillers, 2000; Wang et al., 2010). An important distinction
between these two transport complexes is that RNA granules con-
tain ribosomes while RNA particles do not (Sossin and DesGro-
seillers, 2006). The presence of ribosomes within RNA granules
suggests that the translation of associated mRNAs is blocked at
the step of translational elongation.
RNA binding proteins are present within several other mRNP
complexes that contain translationally repressed mRNAs. In
response to cellular stress, TIA1, TIAR, G3BP, and other RBPs
aggregate to form SGs, which contain untranslated mRNAs
(Buchan and Parker, 2009; Kedersha and Anderson, 2009). SGs
are proposed to safeguard specific mRNAs from destruction dur-
ing cellular stress and, upon relief of the stress signal, disassemble
to allow translationally repressed mRNAs to re-enter translation.
P-bodies are another type of mRNP structure containing non-
translating mRNAs that are destined for degradation (Coller and
Parker, 2005; Teixeira et al., 2005) or are eventually released to
re-associate with polysomes (Brengues et al., 2005). While the
composition of P-bodies is not fully characterized, they generally
contain decapping enzymes, exonucleases, translational repres-
sors, microRNA (miRNA) silencing machinery, and translation-
regulating RBPs, including CPEB, Staufen, and eIF4E (Parker and
Sheth, 2007). Lastly, guided by miRNAs, RISCs repress transla-
tion of target mRNAs at the stage of translation initiation or
elongation (Valencia-Sanchez et al., 2006). RBPs such as FMRP
have been shown to associate with miRISC (Caudy et al., 2002;
Witold, 2005) and can either promote or antagonize the repres-
sive actions of miRISC (Brodersen and Voinnet, 2009). These
translation-silencing mRNPs have been observed to interact with
one another, and some components of SGs overlap with P-bodies
(Kedersha et al., 2005) and miRISCs with P-bodies (Liu et al., 2005;
Edbauer et al., 2010); however, the mechanisms that mediate these
interactions remain to be established.
The interactions between RBPs and mRNAs are dynamic,
allowing mRNAs to move from one mRNP to another in a con-
trolled, bidirectional manner. This is an important feature of
mRNA regulation because it ensures that the post-transcriptional
fate of mRNAs is responsive to intracellular and extracellu-
lar signals. Signaling pathways, which are stimulated by various
intracellular and extracellular cues, largely influence the mRNP
distribution, and thus translational status, of mRNAs by reg-
ulating the expression and/or function of RBPs. For example,
activation of the mTOR signaling results in the phosphoryla-
tion of FMRP (Narayanan et al., 2008); this post-translational
modification affects the ability of FMRP to regulate translation
(Ceman et al., 2003) and associate with RISC complexes (Cheever
and Ceman, 2009). In response to signal-induced synaptic acti-
vation, the RBP Staufen was shown to activate translation by
redistributing target mRNAs from RNA granules to translating
polyribosomes (Krichevsky and Kosik, 2001).
GENOME-WIDE APPROACHES TO STUDY TRANSLATION
Advancements in technologies have significantly improved our
ability to study translation at a genome-wide scale. Highly parallel
techniques such as microarrays and high-throughput sequencing
(deep sequencing) have revolutionized approaches to gene dis-
covery, offering unbiased approaches and may be modified to
investigate specific aspects of RNA regulation. In this section, we
highlight studies that have utilized such technologies to investigate
translational control at the genome-wide level both within neural
and non-neural contexts (summarized in Table 1).
GENE EXPRESSION PROFILING USING MICROARRAYS
With the ability to examine gene expression on a global scale,
microarray studies have provided evidence that diverse popula-
tions of mRNAs are localized at synapses. Martin and colleagues
(Poon et al., 2006) were one of the first groups to examine synap-
tically localized mRNAs in rat neurons by mechanically separating
axonal and dendritic processes from the cell body and perform-
ing microarray analysis on the isolated mRNA. Strikingly, they
found that a significant proportion of synaptic mRNAs encoded
translation factors and regulators, and proposed that this may be
a general mechanism to enhance the capacity for local translation
at synapses. Zhong et al. (2006) performed microarray studies
on rat brain mRNA, which led to the discovery that the reper-
toire of synaptic mRNAs is more diverse than previously thought.
The group not only identified transcripts that encoded translation
factors and regulators, but also transcripts that encoded recep-
tor and channel proteins, signaling molecules, cytoskeleton, and
adhesion proteins, membrane trafficking proteins, and molecules
involved in protein degradation. Additional studies have examined
the synaptic transcriptome within other contexts, such as brain-
derived nerve growth stimulation (Schratt et al., 2004) or neurons
displaying molecular signatures of Alzheimer’s disease (Williams
et al., 2009). Interestingly, results from these and other microarray
studies displayed little overlap, suggesting that a large number of
mRNAs can be sequestered at synapses but that their localization
largely depends on the cellular context.
POLYSOME PROFILING
A widely held view is that mRNA expression correlates closely
with expression of the protein it encodes; this is certainly true
in most instances, but is not always the case (Anderson and
Seilhamer, 1997; Gygi et al., 1999). Indeed, the lack of correla-
tion between mRNA and protein expression is expected given
that multiple mechanisms are in place to control translation of
mRNA. In this regard, microarray studies provide limited insight
into the translational status of mRNA. An alternative approach
called polysome profiling exploits the observation that, in gen-
eral, polysome-associated mRNAs are translationally active. By
separating polysome, monosome, and other mRNP complexes
by centrifugation through a sucrose gradient, well-translated
mRNAs can easily be distinguished from poorly translated mRNAs
(Figure 2A). Morris and colleagues were one of the pioneering
groups that used polysome profiling to examine the transla-
tion state of the transcriptome (Zong et al., 1999). Specifically,
total cytoplasmic extracts from cultured human fibroblasts were
layered onto sucrose gradients and centrifuged to separate the
different mRNP complexes. Transcripts residing in high-density
fractions containing polysome species were examined by microar-
ray analysis to identify well-translated mRNAs (Figure 2A), while
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FIGURE 2 | Schematic of genome-wide methods to study
polysome-associated mRNAs in vitro and in vivo. (A) With polysome
profiling, cytoplasmic lysates from cells are layered onto a sucrose gradient
and undergo centrifugation to separate tRNAs, 40S, 60S, and 80S ribosomes,
and polysomes. Messenger RNAs from fractions corresponding to polysomes
(dashed blue box) are isolated and identified by various approaches.
(B) Engineered bacTRAP mice drive expression of EGFP-tagged L10a, a
ribosomal protein found in polysomes (green ribosomes), from promoters
that are activated in specific cells of the central nervous system.
EGFP-L10a-mRNA complexes are immunopurified from brain tissue from
bacTRAP mice, and associated mRNAs are identified by various techniques.
(C) The RiboTag mouse carries an Rpl22 allele with a floxed wild-type
C-terminal Exon4 followed by a HA-tagged Exon4. When the RiboTag mouse
is crossed with a mouse expressing Cre-recombinase in a cell-type specific
manner, Cre-recombinase activates expression of HA-tagged Rpl22, which
incorporates into polysomes (purple ribosomes). Homogenized tissues from
the offspring are subjected to co-immunoprecipitation using antibodies
against HA, and associated mRNAs are identified by various techniques.
(D) Using ribosome profiling to identify ribosome occupancy on mRNAs,
cycloheximide-treated lysates from cultured cells are digested by micrococcal
nucleases to remove mRNA sequences that are not bound by ribosomes
(left). The resulting monosome complexes are purified by ultracentrifugation
through a sucrose gradient or cushion. Ribosome-protected fragments are
recovered and deep sequenced. In parallel, total mRNA from a similar
preparation of cycloheximide-treated lysate is fragmented and deep
sequenced (right), and serves as a normalizing control.
transcripts sequestered within the low-density fractions were also
examined to identify poorly translated mRNAs.
Polysome profiling has been readily applied to various cellu-
lar contexts and cell types, including neurons (Johannes et al.,
1999; Preiss et al., 2003; Rajasekhar et al., 2003; Schratt et al., 2004;
Iguchi et al., 2006). A study that nicely demonstrated the utility of
polysome profiling examined the widespread inhibition of transla-
tion in response to cellular stress, a process that appears to involve
movement of mRNAs from polysome complexes to P-bodies. The
movement of transcripts from polysomes to P-bodies is thought to
be a general phenomenon in eukaryotic cells, yet evidence to sup-
port this view is based on single-gene studies. To address whether
this view is in fact a general phenomenon or limited to a sub-
set of mRNAs, Arribere et al. (2011) used polysome profiling in
combination with translation inhibitors to measure the transla-
tional activity and ribosome occupancy upon glucose withdrawal
and at different times following glucose re-addition. This study
illustrated the power of genome-wide studies: Arribere and col-
leagues were able to provide mechanistic insight to translational
control based on an examination of the entire transcriptome,
not just representative transcripts. Notably, they showed that a
substantial portion of mRNAs, many of which encode survival fac-
tors, is actively translated during stress; this finding disputed the
prevailing notion that translational inhibition is widespread dur-
ing stress. They also found that re-entry of pre-existing mRNAs,
presumably from P-bodies, into polysomes is restricted to a subset
of mRNAs rather than a general phenomenon as initially proposed
(Brengues et al., 2005; Teixeira et al., 2005; Brengues and Parker,
2007; Hoyle et al., 2007).
As with any technique, polysome profiling has several lim-
itations. From a technical perspective, this technique is labor
intensive and difficult to scale-up (Larsson and Nadon, 2008).
Furthermore, polysome profiling should be performed with uni-
form cell populations due to the heterogenic nature of tran-
scriptomes between cell types; this presents a significant chal-
lenge in performing polysome profiling in vivo. A final con-
sideration concerns the underlying assumption of the tech-
nique that mRNAs bound by multiple ribosomes are trans-
lationally active. Both active and stalled ribosomes have been
shown to co-sediment during isolation of polysome complexes
through sucrose gradients (Sivan et al., 2007), indicating that
polysome profiling does not completely distinguish translation-
ally active from repressed mRNAs. Complementary molecular
studies that directly measure de novo protein synthesis would be
useful to discriminate translating from non-translating polysome-
associated mRNAs. Despite these limitations, polysome profiling
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has been extremely successful in identifying translationally active
mRNAs.
TARGETING RIBOSOMES: IMMUNOPRECIPITATION-BASED METHODS
TO ISOLATE POLYSOMES IN VIVO
Gene expression patterns vary greatly between cell types, thereby
requiring that genome-wide studies be performed using homo-
geneous cell populations. The difficulty of performing polysome
profiling in vivo is due to the challenge of extracting homoge-
neous cell populations in sufficient quantities without affecting
the transcriptome (Okaty et al., 2011). The mammalian brain is an
especially challenging model because of its immense heterogeneity.
Enrichment methods, such as fluorescence-activated cell sorting
or laser-capture microdissection, accurately separate genetically
and/or morphologically distinct cells; however, manipulation of
purified cells during isolation steps may alter the transcriptional
profile (Okaty et al., 2011). These challenges must be addressed in
order to achieve the full benefits of this powerful technique in vivo,
giving us a better understanding of translational control within a
physiologically relevant setting. Two groups independently tack-
led this issue by genetically altering mice to express epitope-tagged
versions of ribosome protein subunits (Heiman et al., 2008; Sanz
et al., 2009). All translated mRNAs are, at one point, associated
with ribosomes; thus affinity purification of epitope-tagged ribo-
somes would allow for isolation of polysome-associated mRNAs.
Heiman and colleagues termed their methodology translating
ribosome affinity purification, or TRAP, which involves a series of
bacterial artificial chromosome transgenic mice, called bacTRAP
mice. In these genetically modified mice, expression of EGFP-
tagged ribosomal protein L10a is driven by defined promoters that
are activated in specific cell types of the central nervous system
(CNS; Figure 2B; Heiman et al., 2008). Heiman and colleagues
used bacTRAP mice that expressed EGFP-L10a from the Drd1a
receptor or Drd2 receptor to isolate polysome-associated mRNA
from striatonigral or striatopallidal cells, respectively, of the mouse
striatum. Cells derived from the brain tissue of these mice were
lysed in cycloheximide-spiked buffer to halt elongating ribosomes.
Polysome-associated RNA corresponding to the specific cell type
was isolated by immunoprecipitating for EGFP-L10a and exam-
ined by microarray analysis. The group demonstrated the power
of TRAP technology by identifying polysome-associated mRNAs
unique to four neuronal populations that are intermixed and mor-
phologically indistinguishable. In an accompanying paper, Doyle
et al. (2008) demonstrated the generality of TRAP with a com-
prehensive study of polysome profiles for 24 additional CNS cell
types.
Using a strategy similar to TRAP, Sanz and colleagues engi-
neered a mouse line called RiboTag that contains three HA tags
inserted into the locus of Rlp22, a gene that encodes a ribosome
protein present within polysomes (Figure 2C; Sanz et al., 2009).
Expression of the Rlp22HA allele depends on Cre recombination
such that in the absence of Cre recombinase only endogenous
(wild-type) Rlp22 is expressed. The group crossed RiboTag mice
with several neuron-specific Cre recombinase-expressing mice.
Brain tissues from the resulting offspring were used to immunop-
urify HA-tagged polysomes and recover associated mRNAs
from specific cell populations expressing Cre recombinase. They
demonstrated that the RiboTag system indeed reliably purifies
mRNAs associated with ribosomes in a cell type specific manner.
The RiboTag strategy has several advantages over TRAP. First,
the RiboTag mouse can be crossed to any Cre recombinase-
expressing mouse line, allowing for polysome profiling of a signif-
icantly greater variety of cell types. In contrast, the TRAP system
requires engineering a separate bacTRAP mouse line for each cell
type of interest. Second, Rlp22HA is expressed at levels similar
to wild-type Rlp22, thereby maintaining the appropriate stoi-
chiometry of ribosomal subunits and kinetics of translation. The
TRAP system instead expresses the EGFP-L10a transgene from
an exogenous promoter, which may result in different levels of
EGFP-L10a compared to wild-type L10a. Third, the TRAP method
recommends using in-house monoclonal antibodies against EGFP,
which is costly for multiple experiments. Alternatively, the Ribo-
Tag method uses commercial anti-HA antibodies that are far more
cost effective. Finally, RiboTag technology has the ability to gen-
erate Rlp22HA-expressing cells (e.g., Rpl22HA-expressing mouse
embryo fibroblasts) that are capable of proliferating indefinitely
in culture dishes, providing an abundant and renewable model for
obtaining ribosome-associated mRNAs by immunoprecipitation
rather than by the laborious process of sucrose gradient centrifu-
gation. This ability is severely limited with the TRAP system since
many of the current bacTRAP mice activate EGFP-L10a expression
in neurons, which do not proliferate in vitro. Overall, the TRAP
and RiboTag technologies provide an efficient and rapid method
of isolating polysome-associated mRNA from a single cell type
in vivo.
RIBOSOME PROFILING
Many studies that have been designed to investigate global trans-
lation typically use genome-wide measurements of mRNA and/or
protein expression as indicators of protein synthesis. However,
transcripts are subject to multiple levels of translational control
rendering mRNA expression an imperfect substitute for pro-
tein synthesis. Global protein expression, as measured by mass
spectrometry, is also a poor proxy of translation since pro-
tein stability also contributes to changes in protein expression.
The most precise measurement of translation is direct quantifi-
cation of protein synthesis. To measure protein synthesis at a
genome-wide level, Weissmann and colleagues developed a tech-
nique called ribosome profiling (Figure 2D) to map the precise
positions of ribosomes within the transcriptome (Ingolia et al.,
2009, 2012). Ribosome profiling involves nuclease digestion of
cell extracts to degrade mRNA that is unprotected by ribosomes,
leaving approximately 28 nucleotide RNA fragments. Individual
ribosome-RNA complexes are isolated by centrifugation through
a sucrose gradient or cushion, followed by a series of purifica-
tion steps to recover the mRNA fragments, such as fragment size
selection by gel electrophoresis and rRNA removal by subtractive
hybridization. Ribosome-protected mRNA fragments (ribosome
footprints) are identified by high-throughput sequencing, reveal-
ing the locations of ribosomes along transcripts at nucleotide-level
resolution.
Ingolia et al. (2009) first demonstrated the utility of ribo-
some profiling for studying translation in Saccharomyces cerevisiae.
The authors showed that ribosome profiling could quantitatively
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measure translational efficiency as defined by the ratio of ribosome
footprint density to total mRNA. Ribosome density proved to be a
much better predictor of protein production than measurements
of mRNA levels. Ribosome density also correlated well, though not
perfectly, with protein expression, suggesting that in some contexts
mass spectrometry does not accurately measure global protein
synthesis. The correlative differences between protein expression
and translation efficiency observed by Ingolia et al. (2009) may be
attributed to protein degradation and such differences could be
exploited to investigate protein stability at a genome-wide level.
In addition to being an optimal tool for genome-wide mea-
surements of protein synthesis, ribosome profiling is capable of
discovering novel regulatory mechanisms of translation. While
ribosome footprints are expected to map to coding regions of
transcripts, a ribosome profiling study in yeast found that a
small fraction of footprints (1.2%) mapped to non-coding regions
(Ingolia et al., 2009). The majority of this 1.2% footprint fraction
mapped to the 5′ UTRs of transcripts, leading to the discovery
of 153 upstream open reading frames (uORFs) of which fewer
than 30 had previously been described. Because ribosome profil-
ing maps ribosome footprints at a resolution such that a three-base
codon periodicity is observed, positional data can be used to
identify frame shifts, non-canonical start codons, and stop codon
readthrough, all of which would predict novel protein isoforms.
As proof-of-principle, Ingolia et al. (2009) uncovered a total of 143
non-canonical (non-AUG) start sites in the yeast transcriptome;
this was a substantial contribution to our knowledge of trans-
lational initiation sites in yeast, having previously known of only
two examples of non-AUG initiation sites (Chang and Wang, 2004;
Tang et al., 2004). Sites of premature translational termination can
also be identified with this technique. Subsequent ribosome pro-
filing studies have been implemented in other model organisms,
including bacterial and mammalian systems (Guo et al., 2010;
Ingolia et al., 2011; Oh et al., 2011; Hsieh et al., 2012). Not surpris-
ingly, these studies also produced a long list of candidate initiation
start sites, alternative reading frames, and uORFs. A comparison of
these features across model systems or among different cell types
will be informative in determining whether translational control
mechanisms are general or specific to individual organisms and
cell types.
Translation is a dynamic process and the kinetics of ribosome
movement along transcripts is an important aspect of translational
control. While the temporally static nature of ribosome profiling
may appear ineffective for the study of translational kinetics, Ingo-
lia et al. (2011) demonstrated otherwise by combining ribosome
profiling with run-off elongation assays. First, cells were treated
with harringtonine to block additional rounds of translation ini-
tiation (Fresno et al., 1977). Cycloheximide was then applied to
cells for various time points afterward, freezing all actively trans-
lating ribosomes. Ribosome positions were then determined by
ribosome profiling and the change in ribosome positioning over
the course of cycloheximide treatment was used to generate a mov-
ing picture of ribosomes. In log phase growing yeast, the rate of
translation appeared to be independent of mRNA class, mRNA
length, or whether mRNAs encoded secreted or cytoplasmic pro-
teins. This adaptation of ribosome profiling will prove useful in
studying the rate of translation in the context of cellular stress or
pathological states where global translation is aberrant (Shenton
et al., 2006).
Another critical aspect of translational kinetics is ribosomal
pausing. Pausing or stalling of elongating ribosomes is a mech-
anism of translational repression and may be caused by steric
hindrance (due to secondary structure of the transcript or by the
exiting nascent peptide), recruitment of low abundance tRNAs to
rare codons, or RBPs such as FMRP (Lovett and Rogers, 1996;
McNulty et al., 2003; Darnell et al., 2011). Ingolia et al. (2011)
reasoned that the ribosome density for a given codon should be
commensurate with the average ribosome dwell time, i.e., slower
ribosome movement across a codon (longer dwell time) should
result in more footprint counts at that codon. Based on this infer-
ence, the group used ribosome profiling to identify thousands of
ribosome pause sites at the resolution of individual codons in the
transcriptome of mouse embryonic stem cells (ESCs). Riboso-
mal pausing was initially described more than 20 years ago (Wolin
and Walter, 1988), yet the mechanisms underlying this process is
not well understood. Recently, ribosome profiling in bacteria was
used to show that a Shine–Dalgarno-like feature in mRNA facil-
itates ribosome pausing (Li et al., 2012), demonstrating that this
technique provides an efficient method to elucidate the molecular
mechanisms of ribosomal pausing.
Similar to polysome profiling, ribosome profiling is technically
challenging and labor intensive. Another consideration regarding
ribosome profiling, as pointed out by Morris (2009), relates to the
use of cycloheximide to halt elongating ribosomes prior to cell
lysate preparation. Although characterized as an inhibitor of elon-
gation, cycloheximide has also been shown to block translation
initiation at similar concentrations used for ribosome profiling
(Obrig et al., 1971) but not at lower concentrations (Lodish, 1971).
If the exposure of cycloheximide to cells is low such that transla-
tion elongation, but not initiation, is negatively affected, this may
allow ribosomes to accumulate at the 5′ end of transcripts and
result in spurious ribosome footprinting patterns. This is espe-
cially relevant to applications of ribosome footprinting where drug
delivery and exposure are difficult to control, for example with
studies using mice. Yet despite these drawbacks, ribosome profil-
ing remains a powerful tool to identify novel uORFs, initiation
start sites, termination sites, and alternative reading frames, and
provide insights on ribosome movement or lack thereof (riboso-
mal pausing) will most certainly lead to the discovery of new and
unexpected modes of translational control.
TARGETING RBPs: IMMUNOPRECIPITATION-BASED METHODS TO
ISOLATE RBP-mRNA COMPLEXES
Key to understanding the role of RBPs in translational con-
trol, and RNA metabolism in general, is identifying their mRNA
targets. Initial genome-wide attempts to identify RBP targets
employed a technique called RNA immunoprecipitation (RIP).
Much like its DNA counterpart chromatin immunoprecipita-
tion, RIP involves formaldehyde crosslinking of proteins to RNA,
followed by immunoprecipitation of the protein-RNA complex.
Protein-bound transcripts are then used to make a cDNA library
that is subjected to microarray analysis. A major concern with
RIP is the low signal to noise ratio: RNA tends to be “sticky”
making the technique vulnerable to extracting non-physiological
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binding partners (Mili and Steitz, 2004). The Darnell group intro-
duced an alternate approach to RBP target identification termed
CLIP for crosslinking and immunoprecipitation (Ule et al., 2003),
which is reviewed in greater detail elsewhere (Darnell, 2010a;
König et al., 2012). Instead of using formaldehyde, CLIP uses
UV irradiation to cement protein-RNA interactions by creating
covalent bonds between proteins and RNA that are within dis-
tances of a few angstroms. Unprotected RNA is removed by partial
digestion with RNase (in the original protocol) or micrococcal
nuclease, which is easily inactivated by EGTA to avoid spurious,
continual RNA digestion throughout the procedure (Yeo et al.,
2009; Zisoulis et al., 2010; Polymenidou et al., 2011). Protein-RNA
complexes are recovered by immunoprecipitation with antibodies
against the protein of interest. Transcript fragments of approx-
imately 60–100 nucleotides in length are released from proteins
and are further processed for sequencing. Several aspects of this
technique make it well suited to study RBP-RNA interactions.
First, the direct interaction between a RBP and its target mRNA is
faithfully preserved, since crosslinking only occurs with RBPs and
mRNA that are within angstrom distances. Second, crosslinking of
direct RBP-mRNA interactions via strong covalent bonds allows
these complexes to be purified under stringent conditions, further
reducing background signal. Third, UV irradiation does not pre-
serve protein–protein interactions, thereby avoiding the possibility
of indirect protein-mRNA interactions.
The first application of CLIP sought to identify RNA targets
of Nova, a neuronal KH-type RBP, which is implicated in parane-
oplastic neurologic degeneration (Darnell, 2010b). In this study,
Ule, Jensen, and colleagues identified 34 candidate mRNA tar-
gets, most of which are involved in neuron function (Ule et al.,
2003). The use of low-throughput sequencing to identify Nova
targets, however, generated a limited dataset and made it dif-
ficult to discern authentic from spurious mRNA targets (50%
false positive rate). To remedy this, the same group performed
a subsequent study in which CLIP was combined with high-
throughput sequencing (HITS-CLIP). This strategy generated a
more robust dataset of Nova targets, confirming, and refining
their previous assertions about Nova as a splicing regulator (Licat-
alosi et al., 2008). Further modifications to the standard CLIP
protocol have improved the crosslinking efficiency. One such
modification called Photoactivatable-Ribonucleoside-Enhanced
Crosslinking and Immunoprecipitation, or PAR-CLIP, uses pho-
toreactive ribonucleoside analogs [e.g., 4-thiouridine (4SU) or
6-thioguanosine], which are incorporated into nascent mRNAs in
live cells (Hafner et al., 2010) or whole organisms (Jungkamp et al.,
2011). Photoreactive ribonucleoside analogs crosslink with pro-
teins more efficiently than endogenous ribonucleotides, thereby
enhancing the signal to noise ratio. During cDNA preparation of
labeled mRNA, crosslinked sites are prone to thymidine to cyti-
dine or guanosine to adenosine transitions (when 4-thiouridine
or 6-thioguanosine is used, respectively), revealing exact loca-
tions of nucleotide-protein interactions. This feature was initially
exploited to identify individual ribonucleotides of a small nucle-
olar RNA that interacted with RBPs (Granneman et al., 2009)
and has since been applied to other RBPs (Hafner et al., 2010).
It is important to note that not all RBPs may be amenable
to PAR-CLIP, such as CUG triplet repeat RNA binding protein
(CELF1; Castello et al., 2012). A further modification of CLIP,
called individual nucleotide resolution CLIP or iCLIP, provided
an alternative approach to locating the exact crosslinking posi-
tion (König et al., 2010). Ule and colleagues took advantage of
the fact that reverse transcriptase arrests at sites of nucleotide-
peptide crosslinking (a peptide remnant of the RBP remains after
proteinase K digestion). The resulting truncated cDNAs are nor-
mally lost during the standard CLIP library preparation, but the
iCLIP protocol was designed to recover and sequence these trun-
cated cDNAs to identify exact crosslinking sites. Using CLIP or its
variants, genome-wide protein-RNA interaction maps have been
assembled for numerous RBPs, including Nova (Ule et al., 2003),
RBFOX2 (Yeo et al., 2009), Argonaute proteins (Chi et al., 2009;
Hafner et al., 2010; Zisoulis et al., 2010; Leung et al., 2011), TDP-43
(Polymenidou et al., 2011; Tollervey et al., 2011), FMRP (Darnell
et al., 2011), and hnRNP proteins (Katz et al., 2010; König et al.,
2010; Huelga et al., 2012).
The ability to systematically uncover RBP target sites within the
transcriptome has provided insights to the role of RBPs in trans-
lational control. Using in vivo PAR-CLIP (iPAR-CLIP), Jungkamp
et al. (2011) proposed several models by which GLD-1, a conserved
germline-specific RBP in C. elegans, functioned as a translational
repressor. Highly conserved 5′UTR GLD-1 binding sites were
discovered near the start codon of target transcripts; this was unex-
pected, since prior studies indicated that GLD-1 primarily targets
the 3′ UTR. Following extensive biochemical validation of their
iPAR-CLIP results, Jungcamp and colleagues proposed that GLD-
1 dimers, as the protein is known to form, bind to the 5′ and 3′
UTRs to promote circularization of mRNA to block translational
initiation (Jungkamp et al., 2011). Alternatively, binding of GLD-
1 near start codons at the 5′ UTR may prevent assembly of the
ribosome.
Another study examined the mechanisms of translational con-
trol by FMRP using CLIP. Darnell et al. (2011) identified FMRP
binding sites within the polysome-associated fraction of the tran-
scriptome by HITS-CLIP and found that a significant portion
of gene targets were involved in neuronal synaptic plasticity
and synaptic-related signaling pathways. The majority of FMRP
binding sites (66%) resided within coding sequences. This was
unexpected given that translational control mechanisms usually
involve binding of RBPs within UTRs. Furthermore, the distrib-
ution of FMRP appeared to be uniform along transcripts. Dar-
nell and colleagues extended these observations to demonstrate
that FMRP directly stalls ribosomes on polysome-associated tran-
scripts, thereby suppressing translation. Given that many of these
FMRP targets are involved in synaptic transmission, it was hypoth-
esized that FMRP functions to represses translation of associated
mRNAs during transit from the soma to synapses, to prevent pre-
mature translation and/or degradation. Upon release of FMRP
from its targets, presumably by signal activation, the transcripts,
already loaded with ribosomes, would be rapidly translated. Given
that the interplay between different RBPs is important for RNA
transport and local synaptic translation, the application of CLIP
to neuronal RBPs will be instrumental in defining their individual
and combinatorial contributions to translational control.
CLIP is accompanied by limitations that are either unique to
particular version or inherent to all (Darnell, 2010a; Ascano et al.,
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2012). The ability of CLIP to capture a representative popula-
tion of RNA targets is influenced by the crosslinking efficiency
between RNA and the protein of interest, nuclease digestion con-
ditions (Kishore et al., 2011), and the specificity and reactivity of
the antibody used to isolate the RBP-RNA complex; these factors
are inherent to all CLIP versions. Crosslinking efficiency will vary
depending on the RNA target sequence and the type of amino acids
available for crosslinking. Nucleic acids are generally more reac-
tive with cysteine, lysine, phenylalanine, tryptophan, and tyrosine
residues, and this residue preference appears to be preserved with
4SU-labeled RNA (Meisenheimer and Koch, 1997; Meisenheimer
et al., 2000). 4SU is generally thought to enhance crosslinking
efficiency compared to unmodified uridine (Hafner et al., 2010),
although this is not always the case (Kishore et al., 2011). A draw-
back of PAR-CLIP is the difficulty in applying this method to whole
animal models other than C. elegans, where uniform exposure of
4SU may not be feasible. Until a method for efficient delivery of
ribonucleoside analogs to other animal models (namely mice) is
established, HITS-CLIP is generally required for in vivo studies.
CHALLENGES AND CONSIDERATIONS FOR GENOME-WIDE
STUDIES IN NEURONS
The application of genome-wide studies to neurobiology is accom-
panied by challenges intrinsic to the neural model system and
genome-wide method being employed. The mammalian CNS is
complex with hundreds of morphologically distinct cell types,
each expressing a unique transcriptome. This presents several chal-
lenges when performing genome-wide studies: purifying homoge-
nous cell populations, isolating cells in a manner that does not
alter gene expression, and obtaining sufficient quantities of cells
for analysis. With regard to the latter issue, some of the techniques
discussed here require up to several tens of micrograms of RNA
for analysis, necessitating a large input of cells. Cultured primary
neurons derived from rodent tissue are a well established model
for studying neurons; however, they do not obviate some of these
challenges, as they may not be completely homogenous and do not
expand in vitro. Furthermore, establishing and maintaining cul-
tured primary neurons are difficult and require extensive training
of the researcher. Neural progenitor cells (NPCs), either differ-
entiated from stem cells or isolated from rodents or humans, are
an alternative in vitro model system. NPCs can be expanded and
differentiated into multiple neuronal cell types, and developing
an efficient differentiation process should yield a fairly homoge-
nous cell population. Importantly, NPCs that were differentiated
from induced pluripotent stem cells (iPSCs) derived from patient
fibroblasts have been shown to recapitulate the molecular phe-
notypes of corresponding neurological diseases (Thonhoff et al.,
2009; Ming et al., 2011), providing valuable models to investi-
gate global translation in neurodegeneration using the methods
described herein. The labor intensive, lengthy, and costly nature of
establishing iPSCs and differentiating them into NPCs is a major
drawback of this system.
Similar to cell culture models, animal models used for genome-
wide analyses are fraught with the challenges mentioned above;
however, some of these challenges may be circumvent with the use
current technologies. To remedy the issue of complex cell hetero-
geneity, the RiboTag and TRAP technologies were created, both
of which expressed tagged versions of ribosomes in a cell type
specific manner to isolate mRNA. While the intended application
of RiboTag and TRAP technologies is for in vivo polysome profil-
ing, conceivably they may be adapted for in vivo ribosome profiling
studies. The application of HITS-CLIP in heterogenic mouse brain
tissue is standard (Licatalosi et al., 2008; Polymenidou et al., 2011),
and in theory the technology required to perform HITS-CLIP in
a cell type specific manner in vivo is obvious. Using transgenic
mice that express a tagged version of the RBP of interest in a cell
type specific manner, HITS-CLIP could easily be implemented
in vivo using an antibody that recognizes the tag. Naturally, adap-
tation of RiboTag or TRAP technologies for ribosome profiling or
transgenic mice for HITS-CLIP will require optimization steps to
ensure a seamless integration.
Lastly, bioinformatic challenges inherent to genome-wide stud-
ies largely center on the issue of interpreting the massive amounts
of raw sequencing data. A convergent problem in analyzing
sequence reads derived from CLIP and ribosome profiling data
is the identification of precise binding sites of RBPs or ribosome
footprints within the RNA transcripts. Thus far, the analysis of
CLIP data relies on inherent assumptions about the binding kinet-
ics of RBPs with their preferred RNA substrates. The RBPs that
have been studied thus far, for example Nova, RBFOX2,Argonaute,
and hnRNP family members (Ule et al., 2003; Yeo et al., 2009;
Hafner et al., 2010; Zisoulis et al., 2010; Leung et al., 2011; Huelga
et al., 2012), tend to interact with several binding sites within a
given substrate very strongly. Computational approaches to iden-
tify precise binding sites (or clusters of reads), known as cluster- or
peak-finding algorithms, have therefore assumed that the major-
ity of reads within an RNA that are below an expected threshold
are not true binding sites and represent experimental noise or arti-
facts. However, other RBPs, such as TDP-43 or FUS/TLS may act in
“scanning” mode on some RNA substrates (unpublished observa-
tions), interacting with many sites with low affinity, rather than a
few sites with high affinity, with nevertheless important biological
effects. Most algorithms are conservative in identifying these low
affinity sites within RNA substrates. Ribosome footprints fall into
this second category of many locations of roughly equal occupancy
with mRNA substrates. Thus while ribosome profiling data can be
used to measure quantitative differences in ribosome occupancy
within RNAs, precise footprint sites such as paused ribosomes
are not effectively identified by existing peak-finding algorithms.
Another glaring concern with analyzing RNA and ribosome bind-
ing data is the dearth of statistical tools to measure whether we
have saturated the potential number of binding sites observed
(one strategy is suggested in Polymenidou et al., 2011), or tech-
niques to measure the rate of false positives and negatives. Lastly,
not all RNA binding sites are functional. It is not unthinkable that
while highly expressed RBPs interact with many RNA substrates,
many, if not most of these sites may not actually have an impact
in regulating the life cycle of the RNA molecule. Integrating other
genome-wide assays that reveal the dependence of the RNA on the
RBP is important for assigning functions to these binding sites.
Thus, computational approaches to integrate these information
with CLIP data, and also comparing how multiple RBPs affect the
same molecules will be crucial in going forward (Huelga et al.,
2012).
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Table 2 | List of RBPs involved in translation and implicated in
neurological diseases.
RBP Function Disease Reference
FMRP Repressor FXS Darnell et al. (2011)
hnRNP A2/B1 Activator ALS, FTLD Kwon et al. (1999)
hnRNP C Activator AD Lee et al. (2010)
IGHMBP2 Regulator SMA Grohmann et al. (2001), de
Planell-Saguer et al. (2009)
Musashi Repressor AD Okano et al. (2002), Perry et al.
(2012)
SMN Putative
repressor
SMA Piazzon et al. (2008)
TDP-43 Repressor ALS, FTLD Lagier-Tourenne et al. (2010)
AD, Alzheimer’s disease; ALS, Amyotrophic lateral sclerosis; FTLD, Frontotempo-
ral lobar dementia; FXS, Fragile X syndrome; SMA, Spinal muscular atrophy.
RNA BINDING PROTEINS AND TRANSLATIONAL CONTROL
IN NEUROLOGICAL DISEASES
RNA binding proteins have received considerable attention for
their roles in neurodegeneration (Lukong et al., 2008; Liu-
Yesucevitz et al., 2011). This is not surprising given that many
RNA processing events, including local translation, are impor-
tant for neuronal function (Klann and Dever, 2004; Sutton and
Schuman, 2006). Of the handful of RBPs that are associated with
neurological diseases, only several have been implicated in the reg-
ulation of translation (Table 2), most of which were determined
by single-gene studies. Presently, there is a lack of genome-wide
studies examining the translation functions of RBPs in normal or
pathological contexts of neurons, with the exception of a few stud-
ies related to FMRP; this leaves much room for investigation. In
this section, we review our current knowledge of these RBPs (listed
in Table 2) with regard to translational control and neurological
diseases.
FMRP is one of the more extensively studied RBPs with
regard to translational regulation and neurodegeneration. It is
essential for proper synaptic function, as loss of FMRP in mice
results in aberrant pre- and post-synaptic plasticity (Deng et al.,
2011). FMRP is present throughout the neuron (soma, den-
drites, and axon) with the majority of FMRP (85–90%) being
associated with polysomes (Zhang and Darnell, 2011). Misreg-
ulation of FMRP is linked with FXS, a condition characterized
by impaired cognitive, physical, emotional, and sensory func-
tion (Bagni and Greenough, 2005; Bassell and Warren, 2008).
Consistent with this, a genome-wide analysis of FMRP RNA tar-
gets using HITS-CLIP revealed that many FMRP targets encode
proteins that are implicated in autism spectrum disorders (Dar-
nell et al., 2011). Mutations within the FMRP gene that lead to
reduced expression are frequently observed in patients with FXS
(De Boulle et al., 1993; Snow et al., 1993). As discussed in this
review, FMRP downregulates target gene expression by blocking
translation in part by stalling ribosomes. FMRP has also been
shown to interact with Ago2 and recruit miRISCs to its mRNA
targets, providing another mechanism by which FMRP medi-
ates gene silencing (Muddashetty et al., 2011). Edbauer et al.
(2010) demonstrated that FMRP associates with miR-125b and
miR-132 in the mouse brain, interactions of which greatly influ-
ence dendritic spine morphology and synaptic physiology of
hippocampal neurons. In this study, a limited set of miRNAs
was examined and it is likely that additional miRNAs interact
with FMRP. Genome-wide methods tailored to studying miRNA-
protein interactions are well established (reviewed in Wilbert
and Yeo, 2011) and would provide an unbiased approach toward
identifying miRNAs that interact with FMRP as well as other
RBPs.
The evolutionarily conserved Musashi family of RBPs, herein
referred to as Musashi, has strong links to both translational
control and neurobiology (Okano et al., 2002). Preferentially
expressed in the mammalian nervous system, Musashi is a key con-
tributor to maintaining the proliferative capacity of neural stem
cells, such that its loss leads to a reduction in the formation of
neurospheres, or cell-cultured neural stem cells (Sakakibara et al.,
2002). Musashi is thought to maintain progenitor self-renewal
by translationally repressing inhibitors of stem cell proliferation.
One of these targets, CDKN1A, encodes the anti-proliferative cell-
cycle inhibitor p21WAF (Battelli et al., 2006). NUMB is another
Musashi target that is a negative regulator of the Notch signal-
ing pathway. Since Notch signaling is crucial for neural stem
cell maintenance (Hitoshi et al., 2002), translational silencing of
NUMB by Musashi augments this proliferative process (Imai et al.,
2001). The mechanism by which Musashi suppresses translation,
at least for NUMB, involves disrupting the eIF4G binding-Poly(A)-
binding protein interaction, thereby preventing assembly of the
80S ribosomal complex (Kawahara et al., 2008). If Musashi is char-
acteristic of most RBPs, then it has hundreds or thousands targets
in addition to NUMB and CDKN1A. Using the iterative in vitro
selection process SELEX, the RNA binding sequence of Musashi
has been identified (Imai et al., 2001). This sequence information
can be useful in predicting targets, yet still requires single-gene
studies to validate authentic Musashi targets. The application of
HITS-CLIP to define Musashi targets and locate discrete binding
sites would prove invaluable toward understanding the function
of Musashi. This knowledge may also be useful to investigate a
potential role of Musashi in Alzheimer’s disease (AD). A link
between Musashi and AD was established with the observation
that Musashi expression was reduced in patients with AD (Perry
et al., 2012). Consistent with Musashi being a key regulator of
neural stem cells, downregulation of Musashi correlated with a
reduction in neural stem cells, the latter event of which is often
observed in AD. Whether misexpression of Musashi is a deter-
minant or downstream effect of AD is uncertain. As will be a
common theme among the RBPs addressed in this section, a
comprehensive understanding of Musashi function as revealed
by genome-wide studies will likely identify therapeutic targets
implicated in AD.
TAR DNA-binding protein-43 (TDP-43) is another RBP that
has recently been recognized as an important contributor to
neurological diseases (Lagier-Tourenne et al., 2010). It is well
established as a regulator of transcriptional repression and alter-
native splicing, but may also have a role in translational repression
(Wang et al., 2008c). In hippocampal neurons, TDP-43 appears
to reside within RNA granules and P-bodies – storage sites of
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repressed mRNAs; this observation is consistent with the finding
that TDP-43 acts as a translational repressor in an in vitro assay
(Wang et al., 2008b). A pathological link between TDP-43 and
neurodegeneration was initially established with the observation
that TDP-43 is present within brain cell inclusions of patients
with ALS or FTLD (Arai et al., 2006; Neumann et al., 2006).
Dominant mutations in the gene encoding TDP-43 (TARDBP)
that cause mislocalization of the protein were subsequently iden-
tified in cohorts of patients with ALS and FTLD (Gitcho et al.,
2008; Kabashi et al., 2008; Sreedharan et al., 2008; Van Deer-
lin et al., 2008; Yokoseki et al., 2008). The aberrant activities of
disease-associated forms of TDP-43 have been recapitulated in
transgenic rats displaying neurological impairments and in repro-
grammed pluripotent stem cells, confirming the pathogenicity of
these mutations (Bilican et al., 2012; Huang et al., 2012). Findings
from genome-wide studies have advanced our understanding of
the pathogenic activities TDP-43 by revealing that TDP-43 modu-
lates the levels and alternative splicing of many of its RNA targets, a
substantial portion of which encode proteins involved in neuronal
development and function (Polymenidou et al., 2011; Tollervey
et al., 2011). A connection between the translational silencing and
alternative splicing functions of TDP-43 may exist, as demon-
strated for the TDP-43 target S6 kinase 1 (S6K1) Aly/REF-like
target (SKAR). TDP-43 appears to control alternative splicing of
SKAR, which results in the expression of a SKAR isoform that can
no longer activate the translation-stimulating SK61-dependent
signaling pathway (Fiesel et al., 2012). Therefore loss of TDP-43
resulted in upregulation of the SKAR isoform that increases SK61
activity and consequently stimulated global translation. Whether
the translational functions of TDP-43 require its splicing activi-
ties for other TDP-43 targets remains elusive. But more pressingly,
the role of TDP-43 in global translation remains unknown and
will best be addressed by employing the genome-wide methods
discussed here.
Two members of the heterogeneous nuclear ribonucleoproteins
(hnRNPs) family of RBPs, hnRNP A2/B1, and hnRNP C, have been
recognized as translational regulators with links to neurological
diseases. As key regulators of RNA metabolism, hnRNP proteins
are widely expressed in various tissues, including the mammalian
brain (Kamma et al., 1995, 1999). In neuroblastoma cells, hnRNP
C was shown to enhance the translation of mRNA that encode
amyloid precursor protein (APP), a protein that, when aberrantly
processed, is the major constituent of cerebral amyloid plaques
found in patients with AD (Lee et al., 2010). By associating with
the same region of APP mRNA as FMRP, hnRNP C prevents FMRP
from binding to and silencing the translation of APP mRNA.
Another hnRNP family member, hnRNP A2/B1, promotes trans-
lation through several mechanisms. It has been show to mediate
transport of specific mRNAs to distant dendrites where they are
translated to produce a local supply of proteins that are required
for synaptic plasticity (Gao et al., 2008). HnRNP A2/B1 was also
shown to control the translation of mRNAs encoding myelin basic
protein and c-Myc through mechanisms that are not well defined
(Kwon et al., 1999; Shi et al., 2011). Similar to TDP-43, hnRNP
A2/B1 is present within brain cell inclusions of some patients with
FXTAS, suggesting that the pathogenic functions of hnRNP A2/B1
involve its mislocalization (Iwahashi et al., 2006).
Several other neurological disease-related RBPs are suggested
to have roles in translation, yet direct experimental evidence to
support such roles is lacking. One example is survival of motor
neuron (SMN), an RBP that is mutated in patients with SMA
(Wirth, 2000). SMA is a fatal autosomal recessive disorder charac-
terized by degeneration of lower motor neurons that ultimately
results in paralysis with muscular atrophy (Lunn and Wang,
2008). SMN is involved in the assembly of the spliceosome, a
complex that carries out gene splicing, and is also required in
the formation of SGs (Liu et al., 1997; Pellizzoni et al., 1998;
Hua and Zhou, 2004). In addition, SMN is found in complexes
with FMRP, and through this association, SMN is hypothesized
to mediate translation (Piazzon et al., 2008). Loss-of-function
mutations in the gene encoding the RBP immunoglobulin µ-
binding protein 2 (IGHMBP2) are also associated with SMA
(Grohmann et al., 2001). Biochemical analysis of IGHMBP2
determined that it physically associates with regulators of tRNA
transcription and ribosome biogenesis, suggesting strong ties to
translational regulation (de Planell-Saguer et al., 2009). The mech-
anism by which defects in SMN and IGHMBP2 cause SMA or
whether either protein has a defined role in translation remains
unknown.
CONCLUSION
Although progress has been made in understanding transla-
tional regulation in neurons, many questions remain unaddressed.
Specifically, our knowledge of RBP function in translation is
very limited. We have yet to discover direct targets of many
neuron-related RBPs and determine how these RBPs influence
ribosome kinetics and the distribution of mRNAs with differ-
ent mRNP complexes. We also do not know whether misregu-
lation of certain RBPs, an event often associated with neurological
diseases, affects global translation and, if so, whether aberrant
translational regulation is an underlying mechanism leading to
disease. Genome-wide methods are well suited to address these
questions, and can provide highly detailed information that will
reveal novel translational control mechanisms. The tool set of
genome-wide methods to study translational control is exten-
sive, and improvements to both the molecular and computational
components of these techniques are ongoing. Since genome-
wide studies have the capacity to produce an overwhelming
amount of data, it is important that key findings be indepen-
dently validated by molecular techniques. Such complementa-
tion between genome-wide and molecular studies will undoubt-
edly provide insights to the basis for translational regulation in
neurons.
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